CD19 CAR T cell product and disease attributes predict leukemia remission durability.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated.

Methods

We analyzed 43 pediatric and young adult subjects participating in a Phase I trial of defined composition CD19CAR T cells (NCT02028455). CAR T cell phenotype, function and expansion, as well as starting material T cell repertoire, were analyzed in relation to therapeutic outcome (defined as achieving complete remission within 63 days) and duration of leukemia free survival and B cell aplasia.

Results

These analyses reveal that initial therapeutic failures (n = 5) were associated with attenuated CAR T cell expansion and/or rapid attrition of functio

SUBMITTER: Finney OC 

PROVIDER: S-EPMC6486329 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature